ARRY-162 (binimetinib) is a reversible MEK1/2 inhibitor which is often used in conjunction with encorafenib in BRAF V600E-mutant metastatic melanoma, NSCLC, and colorectal cancer (107–109). The gene discussed is MAP2K1; the disease is non-small cell lung carcinoma.